| Meridian Behavioral Healthcare, Inc. | |
|
4300 Sw 13th St Gainesville FL 32608-4006 | |
| (352) 374-5600 | |
| (352) 375-0298 |
| Full Name | Meridian Behavioral Healthcare, Inc. |
|---|---|
| Speciality | Community/Behavioral Health |
| Location | 4300 Sw 13th St, Gainesville, Florida |
| Authorized Official Name and Position | Margarita Labarta (PRESIDENT/CEO) |
| Authorized Official Contact | 3523745600 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Meridian Behavioral Healthcare, Inc. 1565 Sw Williston Rd Gainesville FL 32608-4044 Ph: (352) 374-5600 | Meridian Behavioral Healthcare, Inc. 4300 Sw 13th St Gainesville FL 32608-4006 Ph: (352) 374-5600 |
| NPI Number | 1134287154 |
|---|---|
| Provider Enumeration Date | 12/04/2006 |
| Last Update Date | 10/21/2019 |
| Medicare PECOS PAC ID | 7517977812 |
|---|---|
| Medicare Enrollment ID | O20060502000237 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134287154 | NPI | - | NPPES |
| 360344000 | Medicaid | FL |
| Provider Name | Bonnie Boyette Peterson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1194874669 PECOS PAC ID: 2365345998 Enrollment ID: I20040130000110 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Dale F Syfert |
|---|---|
| Provider Type | Practitioner - Addiction Medicine |
| Provider Identifiers | NPI Number: 1164495057 PECOS PAC ID: 4981694486 Enrollment ID: I20040517000420 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | John H Abernethy |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1285676122 PECOS PAC ID: 6103839527 Enrollment ID: I20060801000070 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Joanne M Gibson |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1710026265 PECOS PAC ID: 6204932833 Enrollment ID: I20070427000435 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Sarah Graham Frazier |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1760570352 PECOS PAC ID: 7618078031 Enrollment ID: I20070728000115 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Elaine D Davis |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1447200837 PECOS PAC ID: 2860540028 Enrollment ID: I20090428000536 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Jerris N Grover |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1407002082 PECOS PAC ID: 8123178746 Enrollment ID: I20090602000535 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Linda H Skalsky |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1194837989 PECOS PAC ID: 1052471133 Enrollment ID: I20090722000249 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Carolyn G Ascencios |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1427298645 PECOS PAC ID: 7416083811 Enrollment ID: I20100324000920 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Lynda G Evans |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1114130622 PECOS PAC ID: 0840329702 Enrollment ID: I20100602000569 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Mathew L Nguyen |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1083650261 PECOS PAC ID: 2163556010 Enrollment ID: I20100814000247 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Tonia L Werner |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1487686432 PECOS PAC ID: 6800920661 Enrollment ID: I20100816000248 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Ruth A Jackson |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1811121940 PECOS PAC ID: 3971780859 Enrollment ID: I20110601000418 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Sarah M Dooley |
|---|---|
| Provider Type | Practitioner - Addiction Medicine |
| Provider Identifiers | NPI Number: 1740483932 PECOS PAC ID: 3274607361 Enrollment ID: I20110927000619 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Pamela Lynne Carroll |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1235440074 PECOS PAC ID: 9830356856 Enrollment ID: I20120202000719 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Rhonda K Lynch |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1376698811 PECOS PAC ID: 0345281440 Enrollment ID: I20121217000136 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Stephen A Straubing |
|---|---|
| Provider Type | Practitioner - Addiction Medicine |
| Provider Identifiers | NPI Number: 1184674848 PECOS PAC ID: 2062593627 Enrollment ID: I20130107000174 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Alan H Paulin |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1104969971 PECOS PAC ID: 7214180934 Enrollment ID: I20130109000126 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Robert W Bachus |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1285699025 PECOS PAC ID: 9537143334 Enrollment ID: I20130611000377 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Mardell F Coleman |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1730514217 PECOS PAC ID: 2860626710 Enrollment ID: I20131008000407 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Angela D Seay |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053430314 PECOS PAC ID: 9032343892 Enrollment ID: I20131009002009 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Pamela L Smith |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1508994039 PECOS PAC ID: 2567697816 Enrollment ID: I20131023000556 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Sherri A Ferguson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1669711826 PECOS PAC ID: 3577889229 Enrollment ID: I20150224001409 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Steven D Pinkert |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1144631607 PECOS PAC ID: 1456371350 Enrollment ID: I20151105001350 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Kishan Nallapula |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1265710586 PECOS PAC ID: 3678708773 Enrollment ID: I20160913002913 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Denise L Sanfilippo |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1497172605 PECOS PAC ID: 1658653738 Enrollment ID: I20170125001439 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | David Scott Kirby |
|---|---|
| Provider Type | Practitioner - Addiction Medicine |
| Provider Identifiers | NPI Number: 1386957280 PECOS PAC ID: 8224314075 Enrollment ID: I20170411001377 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Alyssa C Bean |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1851888358 PECOS PAC ID: 3577810175 Enrollment ID: I20180726002840 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Johnnie Bradley-goodman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1306322656 PECOS PAC ID: 0042561078 Enrollment ID: I20181001002367 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Regina B Romblad |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1760802094 PECOS PAC ID: 2769736115 Enrollment ID: I20181121001525 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Lindsey H Vallabhaneni |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1790261139 PECOS PAC ID: 2567708779 Enrollment ID: I20190109001155 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Neta C Maynard |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1609287424 PECOS PAC ID: 5890011498 Enrollment ID: I20190219002387 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Melissa Marie Cross |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1578045407 PECOS PAC ID: 4486814605 Enrollment ID: I20190221000205 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Jamie L Stormer |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1083183115 PECOS PAC ID: 3870831662 Enrollment ID: I20190221001198 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Jennifer L Lacasse |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1194178814 PECOS PAC ID: 2769715127 Enrollment ID: I20190618000550 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Jennifer Tuck |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285282962 PECOS PAC ID: 3476884321 Enrollment ID: I20191008002573 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Nathalie I Hervy |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1366991929 PECOS PAC ID: 5395170740 Enrollment ID: I20200114000800 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Paula Alexander-delpech |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265915235 PECOS PAC ID: 2365878501 Enrollment ID: I20200206000028 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Vonceil Levine |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1588161582 PECOS PAC ID: 1456780444 Enrollment ID: I20200326000385 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Tina Harkness-poirer |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1003321894 PECOS PAC ID: 7214366129 Enrollment ID: I20200327002552 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Paula J Allen |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1679013403 PECOS PAC ID: 8628490232 Enrollment ID: I20200626000206 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Ashley B Watson |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1649789645 PECOS PAC ID: 2466862644 Enrollment ID: I20201028002533 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Antony M Woehle |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275936791 PECOS PAC ID: 2264843564 Enrollment ID: I20201117002073 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Amy L Mccaughan |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1639677495 PECOS PAC ID: 0143633750 Enrollment ID: I20201228001604 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Ezra E Stone |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1356806814 PECOS PAC ID: 3375956923 Enrollment ID: I20201229000653 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Patricia A Bischoff |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1023181419 PECOS PAC ID: 7214003318 Enrollment ID: I20210311000641 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Jennifer E Sebreros |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1043728009 PECOS PAC ID: 1658789961 Enrollment ID: I20210426000761 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Faith Lynn Skodmin |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1487200093 PECOS PAC ID: 6002224359 Enrollment ID: I20210426002192 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Rabecca N Dawson |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1265999403 PECOS PAC ID: 3072912849 Enrollment ID: I20210527000800 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Ijeoma Ofokansi |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1083149447 PECOS PAC ID: 5799175980 Enrollment ID: I20211202000149 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Mutinta Yvonne Tembo |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1003575523 PECOS PAC ID: 1658762943 Enrollment ID: I20211221001030 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Steven M Carney |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1649208026 PECOS PAC ID: 3870617467 Enrollment ID: I20220127000521 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Arthronia N Hosley |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1669631974 PECOS PAC ID: 7719371756 Enrollment ID: I20220308001582 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Sabrina M Brown |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1316172851 PECOS PAC ID: 0446559140 Enrollment ID: I20220427002243 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Elliot D Schmidt |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1881220713 PECOS PAC ID: 4183007479 Enrollment ID: I20220819000165 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Corey Potter |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1992182414 PECOS PAC ID: 6002290756 Enrollment ID: I20220830003815 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Mary E Carrington |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1528600194 PECOS PAC ID: 7517341662 Enrollment ID: I20220908002648 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Sylvie Melman |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1942855184 PECOS PAC ID: 8921479015 Enrollment ID: I20230127002593 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Johanna L Stith |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1225514060 PECOS PAC ID: 9931574506 Enrollment ID: I20230412002748 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Anne Nicole D Dela Cruz |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1609470798 PECOS PAC ID: 7315302254 Enrollment ID: I20230428002012 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Ivey Annette Mitchell |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1851002158 PECOS PAC ID: 9436517968 Enrollment ID: I20230615001443 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | William Seay |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1467951012 PECOS PAC ID: 2062870215 Enrollment ID: I20230620001739 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Belinda Meyn |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1396396354 PECOS PAC ID: 7618338294 Enrollment ID: I20230728002138 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Laure S Gaston |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1407639115 PECOS PAC ID: 0840654166 Enrollment ID: I20230919003536 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Megan C Rhoades |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1457747396 PECOS PAC ID: 6305290727 Enrollment ID: I20231003002934 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
| Provider Name | Jeremiah L Mikell |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1447038088 PECOS PAC ID: 3577918697 Enrollment ID: I20231010002293 |
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
News Archive
The presentation of The Insect Cookbook - Food for a Sustainable Planet on Monday 17 March is an important step to promote insects as the meat for the future in the Western world. The first copy will be presented to professor Louise O. Fresco, the future (as of July 1st) chairperson of the Board of Wageningen UR (University & Research centre)
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
The American Public Health Association (APHA) urges the public to use the current swine flu outbreak as an opportunity to ensure that they and their families are prepared for potential pandemics, disasters or any other health emergencies that may arise.
› Verified 9 days ago
Marc Kepner Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 9224 Nw 59th Ln, Gainesville, FL 32653 Phone: 352-226-8210 | |
A Helping Hand Counseling. Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 408 W University Ave Ste 206b, Gainesville, FL 32601 Phone: 352-519-1537 | |
Dr. Reesa Donnelly Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 3908 Sw 6th Pl, Gainesville, FL 32607 Phone: 352-216-4579 | |
Counseling & Rehabilitation Associates Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5024 Nw 27th Court, Suite B, Gainesville, FL 32606 Phone: 352-378-2600 Fax: 352-378-1828 | |
Village Counseling Center Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 100 Sw 75th St, Suite 107, Gainesville, FL 32607 Phone: 352-331-4621 Fax: 352-331-4681 | |
Catlin Bauer Counseling, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4421 Nw 39th Ave Ste 3, Gainesville, FL 32606 Phone: 352-380-0209 | |
Candor Counseling Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2830 Nw 41st St, Suite J, Gainesville, FL 32606 Phone: 352-284-3747 |